Rinvoq vs Sotyktu
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Rinvoq | US Sotyktu | |
|---|---|---|
| Generic name | upadacitinib | deucravacitinib |
| Drug class | JAK Inhibitor | TYK2 Inhibitor |
| Treats | Rheumatoid arthritis, psoriatic arthritis, eczema | Plaque psoriasis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Bristol-Myers Squibb |
| Year approved | 2019 | 2022 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $175M | $130M |
| Common side effects | Serious infections, Blood clots, Cardiovascular events, Cancer risk | Common cold symptoms, Increased infections, Cold sores, Mouth sores |
Frequently asked questions
Is Rinvoq or Sotyktu better?
Neither is universally "better." Rinvoq (upadacitinib) and Sotyktu (deucravacitinib) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rinvoq and Sotyktu?
Rinvoq is a JAK Inhibitor made by AbbVie, while Sotyktu is a TYK2 Inhibitor made by Bristol-Myers Squibb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rinvoq has the larger estimated TV advertising budget of the two.